Adagrasib Shows Durable Benefit in KRAS-Mutated NSCLC

Adagrasib shows durable clinical benefit in previously treated, advanced KRASG12C-mutated non-small cell lung cancer, including patients with brain metastases.
Medscape Medical News

source https://www.medscape.com/viewarticle/975059?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?